First human trial launches for experimental Cancer-Fighting antibody
NCT ID NCT06178614
Summary
This early-stage study is testing a new experimental drug called JNJ-87890387 in people with advanced solid tumors that have spread or cannot be surgically removed. The main goals are to find a safe dose and understand how the body handles the drug. The trial is enrolling 200 adults with specific advanced cancers including kidney, ovarian, uterine, colorectal, and lung cancers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centre Leon Berard
RECRUITINGLyon, 69008, France
-
Hosp Univ Vall D Hebron
RECRUITINGBarcelona, 08035, Spain
-
Hosp. Univ. 12 de Octubre
RECRUITINGMadrid, 28041, Spain
-
Institut Gustave Roussy
RECRUITINGVillejuif, 94805, France
-
Sarah Cannon Research Institute
RECRUITINGNashville, Tennessee, 37203, United States
-
Start Midwest
RECRUITINGGrand Rapids, Michigan, 49546, United States
Conditions
Explore the condition pages connected to this study.